Search - tctmd.com

Displaying 21 - 40 of 59

Sort: Relevancy | Date

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

October 13, 2021

Infective Endocarditis Rare After AVR, but Often a Killer When It Occurs

News Daily News

Infective Endocarditis Rare After AVR, but Often a Killer When It Occurs

Michael O'Riordan

October 01, 2021

STEP Trial Supports Lower BP Goal in Older Patients With Hypertension

News Conference News ESC 2021

STEP Trial Supports Lower BP Goal in Older Patients With Hypertension

August 30, 2021

New VARC-3 Definitions Provide a Road Map for Future Aortic Valve Research

News Daily News

New VARC-3 Definitions Provide a Road Map for Future Aortic Valve Research

Michael O'Riordan

April 23, 2021

New Advanced Training Outlined for Future Vascular Medicine Specialists

News Daily News

New Advanced Training Outlined for Future Vascular Medicine Specialists

Michael O'Riordan

January 21, 2021

The Hope Dealers: How Clinicians and New Tech Could End Unnecessary PAD Amputations

News Features

The Hope Dealers: How Clinicians and New Tech Could End Unnecessary PAD Amputations

December 24, 2020

Tragedy as Catalyst: How COVID-19 May Transform Clinical Research for Good

News Features

Tragedy as Catalyst: How COVID-19 May Transform Clinical Research for Good

December 14, 2020

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

News Conference News AHA 2020

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

Michael O'Riordan

November 17, 2020

More Circulating Omega-3s May Boost Prognosis After STEMI

News Daily News

More Circulating Omega-3s May Boost Prognosis After STEMI

October 26, 2020

US Sees Drop in Hypertension Control

News Daily News

US Sees Drop in Hypertension Control

September 10, 2020

Pulmonary Embolism in COVID-19 Patients: New Numbers, Little Consensus

News Daily News

Pulmonary Embolism in COVID-19 Patients: New Numbers, Little Consensus

Michael O'Riordan

April 29, 2020

COVID-19 Lockdown Inactivity May Spell Trouble for CVD Prevention

News Features

COVID-19 Lockdown Inactivity May Spell Trouble for CVD Prevention

Michael O'Riordan

April 24, 2020

Patient-Level Data Strengthen Rosiglitazone-CV Link: Meta-analysis

News Daily News

Patient-Level Data Strengthen Rosiglitazone-CV Link: Meta-analysis

February 07, 2020

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

News Features

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

December 10, 2019

Grief and CVD: Simple Regimen May Lower Risk

News Daily News

Grief and CVD: Simple Regimen May Lower Risk

November 19, 2019

TCTMD’s Top 10 Most Popular Stories for October 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2019

October 31, 2019

Polypill Drops BP, LDL Cholesterol in a Disadvantaged US Population

News Daily News

Polypill Drops BP, LDL Cholesterol in a Disadvantaged US Population

September 18, 2019

Nonphysician, Community Intervention Curbs CV Risk Factors: HOPE 4

News Conference News ESC 2019

Nonphysician, Community Intervention Curbs CV Risk Factors: HOPE 4

Michael O'Riordan

September 02, 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

August 22, 2019

RAS Inhibition After TAVR Gains More Support, but RCT Still Needed

News Daily News

RAS Inhibition After TAVR Gains More Support, but RCT Still Needed

July 29, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.